HCA Healthcare vs Lilly (Eli)
Side-by-side comparison of AI visibility scores, market position, and capabilities
Largest US for-profit hospital network with ~190 hospitals; $70.7B FY2024 revenue; AI clinical decision support reducing preventable mortality; Sun Belt demographics advantage; NYSE: HCA.
About
HCA Healthcare is the largest for-profit hospital system in the United States, founded in 1968 by Jack Massey, Dr. Thomas Frist Sr., and Dr. Thomas Frist Jr. in Nashville, Tennessee, where it remains headquartered and trades on NYSE (HCA). The company operates approximately 190 hospitals and 2,400 ambulatory care sites—including surgery centers, physician clinics, and urgent care facilities—across 20 U.S. states and the United Kingdom, serving over 37 million patients annually. For FY2024, HCA generated approximately $70.7 billion in revenues under CEO Samuel Hazen, continuing a multi-year growth trajectory driven by hospital volume recovery, acuity mix improvement, and strategic investments in ambulatory care that intercept patients in lower-cost settings before they require inpatient hospitalization.
Indianapolis pharma leader (NYSE: LLY) $45.1B FY2024 revenue (+32%); Mounjaro $11.4B + Zepbound $4.9B tirzepatide GLP-1, oral orforglipron Phase 3, $18B manufacturing expansion competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Health Care component — discovering, developing, and commercializing medicines across diabetes, obesity, oncology, immunology, and neuroscience through approximately 43,000 employees worldwide. In fiscal year 2024, Eli Lilly reported revenues of $45.1 billion (+32% year-over-year) — driven by the historic commercial launch of Mounjaro (tirzepatide for type 2 diabetes, $11.4B revenue) and Zepbound (tirzepatide for obesity and obstructive sleep apnea, $4.9B revenue) — making Eli Lilly one of the fastest-growing large pharmaceutical companies in history and elevating its market capitalization above $700 billion at peak 2024 valuation, briefly making Lilly the most valuable healthcare company globally. CEO Dave Ricks' strategic investment in tirzepatide manufacturing capacity — committing $18+ billion to new US manufacturing sites in Indiana, Wisconsin, and North Carolina — reflects Lilly's execution of unprecedented pharmaceutical demand that has consistently outpaced supply since Mounjaro's 2022 approval and Zepbound's 2023 FDA approval for obesity. The GLP-1/GIP dual agonist mechanism (tirzepatide activates both GLP-1 and GIP incretin receptors, versus semaglutide's single GLP-1 activation) produces superior efficacy results — SURMOUNT-1 trial showing 22.5% average body weight loss with tirzepatide versus 15% with semaglutide (Ozempic/Wegovy) — establishing tirzepatide as the most effective approved obesity pharmacotherapy.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.